Fatih Gürler

Dr. Fatih Gürler

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
AEAbdulsamet Erden
Abdulsamet Erden
AFAntonis Fanouriakis
Antonis Fanouriakis
LKLevent Kilic
Levent Kilic
ASAlper Sari
Alper Sari
BABerkan Armağan
Berkan Armağan
DBDimitrios T. Boumpas
Dimitrios T. Boumpas
Background/aim: Neonatal lupus erythematosus (NLE) is an autoimmune syndrome caused by transplacental transmission of maternal autoantibodies, often with devastating consequences. The objective of this systematic literature review was to analyze the demographic data, geoepidemiology, clinical, and serological characteristics associated with NLE. Materials and methods: We performed a systematic literature search of the Pubmed database covering the period from 1976 to August 2015, using the MeSH terms "neonatal lupus" or "congenital heart block". To be included in the study, articles of any type (original articles, case series, and case reports) had to report on infants with NLE on an individualized (i.e. patient-by-patient) basis. Results: A total of 198 studies were included in the review, reporting on a total of 755 NLE patients. The most frequently reported clinical manifestations of NLE were congenital heart block (CHB, 65.2%), cutaneous lupus (33.1%), and cytopenias (15.5%). We found differences in NLE characteristics based on study geographical origin, with CHB being much more frequent in patients of European or American descent (49.4% and 35%, respectively), while reports originating from Asia reported a higher prevalence of skin involvement (45.2%). Most CHB cases (72.9%) were diagnosed between the 18th and 26th week of gestation. Conclusions: Phenotypic differences of NLE depending on race and country may reflect true pathophysiologic differences or methodologic discrepancies. While maternal autoimmune disease is not a prerequisite for the development of NLE, the existence of a truly "immunonegative" CHB is questionable.

21 August 2021 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
BHBurak Hazir
Burak Hazir
BŞBerkay Şímșek
Berkay Şímșek
AEArzu Erdemír
Arzu Erdemír
FGFatih Gürler
Fatih Gürler
OYOzan Yazıcı
Ozan Yazıcı
UAUtku Aydíl
Utku Aydíl

12 July 2021 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
FGFatih Gürler
Fatih Gürler
AİAyşegül İlhan
Ayşegül İlhan
DGDeniz Can Güven
Deniz Can Güven
OTOkan Turhan
Okan Turhan
BIBediz Kurt İnCi
Bediz Kurt İnCi
AÖAhmet Özet
Ahmet Özet
We aimed to compare the efficacy and the safety of the FOLFOX and the FLOT regimens in metastatic gastric cancer (mGC) as first-line treatment. It was a retrospective multicenter observational study. The comparisons between groups were conducted in terms of progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and hematologic adverse events. Seventy-nine patients, diagnosed with mGC between March 2012 and December 2019, treated with FOLFOX (n = 43) or FLOT (n = 36) regimens as first-line treatment were included in the study. The mPFS was 10.9 months [95% confidence interval (CI), 5.8–16.1] in the FLOT arm and 7.1 months (95% CI, 5.1–9.1) in the FOLFOX arm (P < 0.001). The ORR was 63.9% in the FLOT arm and 30.2% in the FOLFOX arm (P = 0.003). The mOS was 13.3 months (95% CI, 11.3–15.4) in the FLOT arm and 10.9 months (95% CI, 8.2–13.5) in the FOLFOX arm (P = 0.103). The hematologic adverse events in all grades were 88.4% (n = 38) in the FOLFOX arm compared with 80.6% (n = 29) in the FLOT arm (P = 0.335). The FLOT regimen might be a preferred option in mGC with an improved PFS and ORR compared with the FOLFOX regimen.

25 June 2020 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
OSOsman Sutcuoglu
Osman Sutcuoglu
OAOrhun Akdoğan
Orhun Akdoğan
BİBediz Kurt İnci
Bediz Kurt İnci
FGFatih Gürler
Fatih Gürler
NÖNuriye Özdemir
Nuriye Özdemir
OYOzan Yazıcı
Ozan Yazıcı

1 January 2022 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
FGFatih Gürler
Fatih Gürler
DGDeniz Can Guven
Deniz Can Guven
EAErgin AYDEMİR
Ergin AYDEMİR
OSOsman Sutcuoglu
Osman Sutcuoglu
BİBediz Kurt İnci
Bediz Kurt İnci
OYOzan Yazıcı
Ozan Yazıcı
Background/aim: The aim of our study was to compare the efficacy and the safety of the FLOT and the modified DCF (mDCF) regimens in patients with metastatic gastric (GC) and gastroesophageal junction (GEJ) adenocarcinoma as first-line treatment. Materials and methods: The medical records of 72 patients were retrospectively reviewed. Survivals and hematological adverse events of the patients were examined. Factors affecting survivals were analyzed in univariate analysis. A multivariate analysis was performed with the factors contributing to survivals in univariate analysis. Results: The median PFS (mPFS) was 10.1 months (95% CI, 6.8?13.4) in the FLOT arm (n = 33) and 7.4 months (95% CI, 9.1?21.6) in the mDCF arm (n = 39) (p = 0.041). The median OS (mOS) was 12.9 months (95% CI, 9.7?16.1) in the FLOT arm and 15.4 months (95% CI, 9.1?21.6) in the mDCF arm (p = 0.622). It was found that all grade neutropenia was 51.3% vs. 72.7% (p = 0.063), febrile neutropenia was 8.3% vs. 6.3% (p = 0.743), and thrombocytopenia was 48.7% vs. 51.5% (p = 0.813) in the FLOT and mDCF arms, respectively. Anemia was 59% in the FLOT arm and 100% in the mDCF arm (p < 0.001). Grade 3-4 anemia was 7.7% in the FLOT arm and 24.2% in the mDCF arm (p = 0.052). Conclusion: It was shown that the mPFS was significantly increased in the FLOT arm compared to the mDCF arm as the first-line treatment in patients with metastatic GC and GEJC. Hematological adverse events were more favorable in the FLOT arm than in the mDCF arm.

6 May 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VAVolkan Aslan
Volkan Aslan
AKAtiye Cenay Karabörk Kılıç
Atiye Cenay Karabörk Kılıç
NCNigar Rustamova Cennet
Nigar Rustamova Cennet
TYTalha Alperen Yücel
Talha Alperen Yücel
BİBediz Kurt İnci
Bediz Kurt İnci
OYOzan Yazıcı
Ozan Yazıcı
Introduction Immune checkpoint inhibitors (ICIs) targeting PD-1 and PD-L1 have emerged as promising treatments for advanced NSCLC patients without actionable mutations. However, predicting treatment response remains challenging, especially in second-line settings. Although PD-L1 is the only validated biomarker, additional prognostic tools are needed. Systemic inflammation markers such as the neutrophil-to-lymphocyte ratio (NLR) show potential but remain underused. Myeloid-derived suppressor cells (MDSCs), linked to immunotherapy resistance, are associated with increased splenic volume. Therefore this study introduces a splenic index score, combining pre-immunotherapy splenic volume and NLR, to evaluate its prognostic value in NSCLC patients treated with nivolumab in the second-line setting. We analyzed 50 patients with metastatic non-small cell lung cancer (NSCLC) who received nivolumab as second-line or later therapy. Baseline splenic volume and neutrophil-to-lymphocyte ratio (NLR) were assessed using imaging and laboratory data prior to nivolumab initiation. The Splenic Index Score for each patient was calculated using the formula: (baseline splenic volume) × (NLR). Additionally, we evaluated the impact of other factors, including body mass index (BMI), tumor PD-L1 expression, Eastern Cooperative Oncology Group (ECOG) performance status, and sites of metastasis. The median Splenic Index score was 877.3 (range: 180–4830). A higher Splenic Index score was significantly associated with worse overall survival (OS) and progression-free survival (PFS) (p = 0.001 and p = 0.03, respectively). Specifically, patients with a high Splenic Index score had a median PFS of 3 months, compared to 8 months in those with a low Splenic Index score (HR 1.96, 95% CI 1-3.7, p = 0.03). Similarly, the median OS was 4 months for patients with a high Splenic Index score, while it was 15 months for those with a low score (HR 3.5, 95% CI 1.6–7.3, p = 0.001). Baseline splenic volume, basal NLR, and tumor PD-L1 expression were also evaluated; however, no significant differences in PFS or OS were observed for these parameters. Our study demonstrates that the splenic index score, derived from combining radiological and peripheral inflammatory biomarkers, serves as a predictive tool for progression-free survival (PFS) and overall survival (OS) in metastatic NSCLC patients receiving second-line nivolumab therapy.